Kymera Therapeutics (KYMR) closed at $110.76 on October 23, 2026, down 0.1% from the previous close, on volume of 492,115 shares (30-day average 811,248).
Data as of October 23, 2026.
Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026
Globe Newswire (Thu, 22-Oct 4:01 PM ET)
Cathie Wood's weekly recap: adds to CoreWeave, Meta, Recursion; cuts Personalis, Toast
Seeking Alpha News (Mon, 19-Oct 7:05 AM ET)
PRNewswire (Mon, 12-Oct 9:31 AM ET)
Kuehn Law Encourages Investors of Kymera Therapeutics, Inc. to Contact Law Firm
PRNewswire (Wed, 30-Sep 8:59 AM ET)
Kymera Therapeutics to Participate in Upcoming September Investor Conferences
Globe Newswire (Wed, 2-Sep 4:01 PM ET)
Globe Newswire (Tue, 1-Sep 7:00 AM ET)
Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update
Globe Newswire (Wed, 5-Aug 7:00 AM ET)
Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026
Globe Newswire (Tue, 28-Jul 4:01 PM ET)
Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer
Globe Newswire (Mon, 27-Jul 4:01 PM ET)
Market Chameleon (Thu, 25-Jun 6:33 AM ET)
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Kymera Therapeutics trades on the NASDAQ stock market under the symbol KYMR.
As of October 23, 2026, KYMR stock price declined to $110.76 with 492,115 million shares trading.
KYMR has a beta of 0.82, meaning it tends to be less sensitive to market movements. KYMR has a correlation of 0.04 to the broad based SPY ETF.
KYMR has a market cap of $9.21 billion. This is considered a Mid Cap stock.
Last quarter Kymera Therapeutics reported $65 million in Revenue and -$.62 earnings per share. This beat revenue expectation by $32 million and exceeded earnings estimates by $.10.
In the last 3 years, KYMR traded as high as $130.05 and as low as $9.60.
The top ETF exchange traded funds that KYMR belongs to (by Net Assets): VTI, IWM, VB, XBI, VBK.
KYMR has outperformed the market in the last year with a price return of +98.5% while the SPY ETF gained +14.9%. However, in the short term, KYMR had mixed performance relative to the market. It has underperformed in the last 3 months, returning +0.4% vs +1.9% return in SPY. But in the last 2 weeks, KYMR shares have fared better than the market returning +1.3% compared to SPY -1.8%.
KYMR support price is $107.24 and resistance is $114.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that KYMR shares will trade within this expected range on the day.
